AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Amer Sports, Inc. (AS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company has successfully reduced its debt-to-equity ratio to 0.15, the current P/E of 44.96 warrants caution regarding the sustainability of premium growth amidst seasonal cash flow volatility.
Amer Sports, Inc. (AS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Amer Sports, Inc. (AS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 19, 2026 | $0.38vs $0.31+24.1% | $1.9Bvs $1.8B+5.9% |
| Q1 2026 | Feb 24, 2026 | $0.31vs $0.28+11.0% | $2.1Bvs $2.0B+5.3% |
| Q4 2025 | Nov 18, 2025 | $0.33vs $0.25+31.0% | $1.8Bvs $1.7B+2.1% |
| Q3 2025 | Aug 19, 2025 | $0.06vs $0.02+143.2% | $1.2Bvs $1.2B+5.0% |
Recent stock market news and headlines for Amer Sports, Inc. (AS)
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Key metrics vs top competitors for Amer Sports, Inc. (AS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.03 | $19.68B | 44.78 | 26.68% | 6.51% | 7.89% | — | |
| $43.21 | $63.94B | 20.00 | -9.84% | 4.84% | 16.41% | — | |
| $6.74 | $2.88B | -5.81 | -3.86% | -9.94% | -30.13% | — | |
| $64.03 | $3.35B | 19.76 | 0.84% | 4.98% | 10.26% | — | |
| $16.45 | $6.44B | 25.70 | 1.06% | 2.65% | 15.92% | — | |
| $395.31 | $24.11B | 26.16 | 14.63% | 11.6% | 34.77% | — |
Amer Sports, Inc. (AS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when AS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amer Sports, Inc. (AS) stock FAQ — growth, dividends, profitability & financials explained
Amer Sports, Inc. (AS) reported $7.04B in revenue for fiscal year 2025. This represents a 188% increase from $2.45B in 2020.
Amer Sports, Inc. (AS) grew revenue by 26.7% over the past year. This is strong growth.
Yes, Amer Sports, Inc. (AS) is profitable, generating $457.4M in net income for fiscal year 2025 (6.5% net margin).
Amer Sports, Inc. (AS) has a return on equity (ROE) of 7.9%. This is below average, suggesting room for improvement.
Amer Sports, Inc. (AS) generated $476.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.